OPKO Health (NASDAQ:OPK) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• OPKO Health has received a new "sell (D-)" rating from Weiss Ratings, indicating analysts' negative outlook on the stock.
• The company's recent earnings report revealed a loss of ($0.19) EPS, falling short of expectations, with a 13.9% decline in revenue compared to the previous year.
• CEO Phillip Frost made a significant purchase, acquiring 675,000 shares at an average price of $1.32, increasing his ownership stake in the company.

OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

A number of other analysts have also issued reports on OPK. Zacks Research raised OPKO Health from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, OPKO Health currently has a consensus rating of "Moderate Buy" and an average target price of $2.63.

OPKO Health Stock Down 1.3%

Shares of NASDAQ OPK opened at $1.50 on Friday. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -6.00 and a beta of 1.50. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. OPKO Health has a 52-week low of $1.11 and a 52-week high of $2.04. The business's 50 day moving average is $1.45 and its two-hundred day moving average is $1.38.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million during the quarter, compared to analysts' expectations of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm's revenue for the quarter was down 13.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.01) EPS. Research analysts predict that OPKO Health will post -0.25 EPS for the current year.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the company's stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the purchase, the chief executive officer directly owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 49.69% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently modified their holdings of OPK. Oak Thistle LLC acquired a new position in shares of OPKO Health in the first quarter worth $26,000. GM Advisory Group LLC acquired a new position in shares of OPKO Health during the first quarter worth $33,000. Cerity Partners LLC acquired a new position in shares of OPKO Health during the first quarter worth $36,000. Arrow Financial Corp acquired a new position in shares of OPKO Health during the third quarter worth $39,000. Finally, Fisher Asset Management LLC acquired a new position in shares of OPKO Health during the second quarter worth $40,000. Institutional investors and hedge funds own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.